Pravin U. Dugel, MD, is President. Dr. Dugel was previously Managing Partner, Retinal Consultants of Arizona and the Retinal Research Institute; Clinical Professor, USC Eye Institute, Keck School of Medicine, University of Southern California; and Founding Member, Spectra Eye Institute in Sun City, Arizona. Dr. Dugel has authored more than 200 papers, 35 book chapters, and has been invited to lecture at several marquis medical meetings and to serve as a visiting professor at universities worldwide, including in Japan, India, China, Malaysia, Egypt, the United Kingdom, France, Germany, Austria, Italy, Poland, Denmark, Norway, Czechoslovakia, Canada, and Australia. He is on the editorial board of several major medical journals. Dr. Dugel is internationally recognized as a major clinical researcher and has been a principal investigator in over 100 multicenter clinical trials. His research and educational contributions earned him the prestigious Senior Honor Award from the American Academy of Ophthalmology (AAO). He has been elected and previously served as the Retina Subspecialty Day Board Chairman for the American Academy of Ophthalmology Annual Meeting, as a member of the board of directors of the largest retina society in the United States, the American Society of Retina Specialists (ASRS), and the largest retina society in Europe, EURETINA.
Dr. Dugel is a member of the board of directors and current Chair of Orbis International’s Medical Advisory Board/Medical Strategic Committee. Orbis International is a non-profit organization focused on ophthalmology training and education in the developing world. With Orbis, Dr. Dugel travels to developing countries to teach surgical techniques to local ophthalmologists and provide free surgery for those suffering from preventable blindness.
Dr. Dugel graduated summa cum laude from Columbia University in New York City. He then attended UCLA School of Medicine. He completed his residency in ophthalmology at the USC Eye Institute, Keck School of Medicine. Thereafter, he completed his medical retina fellowship at the Bascom Palmer Eye Institute and his surgical retina fellowship at the USC Eye Institute, where he was elected to serve on the faculty as the Resident Director.
What is Pravin Dugel's net worth?
The estimated net worth of Pravin Dugel is at least $140.64 million as of February 24th, 2025. Dr. Dugel owns 3,520,318 shares of IVERIC bio stock worth more than $140,636,704 as of March 6th. This net worth estimate does not reflect any other investments that Dr. Dugel may own. Additionally, Dr. Dugel receives an annual salary of $984,820.00 as EVP at IVERIC bio. Learn More about Pravin Dugel's net worth.
How old is Pravin Dugel?
Dr. Dugel is currently 59 years old. There are 5 older executives and no younger executives at IVERIC bio. The oldest executive at IVERIC bio is Mr. Glenn P. Sblendorio M.B.A., CEO & Director, who is 67 years old. Learn More on Pravin Dugel's age.
What is Pravin Dugel's salary?
As the EVP of IVERIC bio, Inc., Dr. Dugel earns $984,820.00 per year. The highest earning executive at IVERIC bio is Mr. Glenn P. Sblendorio M.B.A., CEO & Director, who commands a salary of $1,360,000.00 per year. Learn More on Pravin Dugel's salary.
How do I contact Pravin Dugel?
The corporate mailing address for Dr. Dugel and other IVERIC bio executives is ONE PENN PLAZA 35TH FLOOR, NEW YORK NY, 10119. IVERIC bio can also be reached via phone at (609) 474-6755 and via email at kathy.galante@ivericbio.com. Learn More on Pravin Dugel's contact information.
Has Pravin Dugel been buying or selling shares of IVERIC bio?
Pravin Dugel has not been actively trading shares of IVERIC bio in the last ninety days. Most recently, Pravin Dugel sold 28,301 shares of the business's stock in a transaction on Monday, April 5th. The shares were sold at an average price of $6.34, for a transaction totalling $179,428.34. Following the completion of the sale, the executive vice president now directly owns 50,000 shares of the company's stock, valued at $317,000. Learn More on Pravin Dugel's trading history.
Who are IVERIC bio's active insiders?